NCT00409175 - Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Familial Amyloid Polyneuropathy

Interventions

DRUG

Fx-1006A

Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

DRUG

Placebo

Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

Trial Locations (10)

Universitatsklinikum Munster, Transplant Hepatology, Münster

CHU de Bicetre, Le Kremlin-Bicêtre

MGH Neuropathy Laboratory, Boston

FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires

Hospital Universitário Prof. Clementino Fraga Filho-UFRJ, Rio de Janeiro

Serviço de Neurologia-Hospital de Santa Maria, Lisbon

Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto

Hospital Clinic de Barcelona, Barcelona

Umea University Hospital, Umeå

Kings College Hospital, London